Pei York, Obaji James, Dupuis Annie, Paterson Andrew D, Magistroni Riccardo, Dicks Elizabeth, Parfrey Patrick, Cramer Benvon, Coto Eliecer, Torra Roser, San Millan Jose L, Gibson Robert, Breuning Martijn, Peters Dorien, Ravine David
Division of Nephrology, University of Toronto, 8N838, 585 University Avenue, Toronto, Ontario, Canada.
J Am Soc Nephrol. 2009 Jan;20(1):205-12. doi: 10.1681/ASN.2008050507. Epub 2008 Oct 22.
Individuals who are at risk for autosomal dominant polycystic kidney disease are often screened by ultrasound using diagnostic criteria derived from individuals with mutations in PKD1. Families with mutations in PKD2 typically have less severe disease, suggesting a potential need for different diagnostic criteria. In this study, 577 and 371 at-risk individuals from 58 PKD1 and 39 PKD2 families, respectively, were assessed by renal ultrasound and molecular genotyping. Using sensitivity data derived from genetically affected individuals and specificity data derived from genetically unaffected individuals, various diagnostic criteria were compared. In addition, data sets were created to simulate the PKD1 and PKD2 case mix expected in practice to evaluate the performance of diagnostic criteria for families of unknown genotype. The diagnostic criteria currently in use performed suboptimally for individuals with mutations in PKD2 as a result of reduced test sensitivity. In families of unknown genotype, the presence of three or more (unilateral or bilateral) renal cysts is sufficient for establishing the diagnosis in individuals aged 15 to 39 y, two or more cysts in each kidney is sufficient for individuals aged 40 to 59 y, and four or more cysts in each kidney is required for individuals > or = 60 yr. Conversely, fewer than two renal cysts in at-risk individuals aged > or = 40 yr is sufficient to exclude the disease. These unified diagnostic criteria will be useful for testing individuals who are at risk for autosomal dominant polycystic kidney disease in the usual clinical setting in which molecular genotyping is seldom performed.
常染色体显性遗传性多囊肾病的高危个体通常采用源自携带PKD1基因突变个体的诊断标准,通过超声进行筛查。携带PKD2基因突变的家庭,其疾病通常不太严重,这表明可能需要不同的诊断标准。在本研究中,分别对来自58个PKD1家庭和39个PKD2家庭的577名和371名高危个体进行了肾脏超声检查和分子基因分型。利用来自基因受累个体的敏感性数据和基因未受累个体的特异性数据,对各种诊断标准进行了比较。此外,还创建了数据集,以模拟实际中预期的PKD1和PKD2病例组合,来评估未知基因型家庭诊断标准的性能。由于检测敏感性降低,目前使用的诊断标准对携带PKD2基因突变的个体效果欠佳。在未知基因型的家庭中,对于15至39岁的个体,存在三个或更多(单侧或双侧)肾囊肿足以确诊;对于40至59岁的个体,每个肾脏有两个或更多囊肿足以确诊;对于60岁及以上的个体,则每个肾脏需要有四个或更多囊肿。相反,40岁及以上的高危个体中肾囊肿少于两个足以排除该病。这些统一的诊断标准将有助于在很少进行分子基因分型的常规临床环境中,对常染色体显性遗传性多囊肾病的高危个体进行检测。